Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04211337
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT04204850
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Centre Francois Baclesse
- Target Recruit Count
- 57
- Registration Number
- NCT04205799
- Locations
- 🇫🇷
Institut de cancérologie de l'Ouest, Nantes, France
🇫🇷Centre François Baclesse, Caen, France
🇫🇷Institut CURIE, Saint-Cloud, France
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
- Conditions
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8Unresectable LeiomyosarcomaStage IIIC Uterine Corpus Leiomyosarcoma AJCC v8Stage IV Uterine Corpus Leiomyosarcoma AJCC v8Metastatic LeiomyosarcomaUnresectable Soft Tissue SarcomaMetastatic Soft Tissue SarcomaStage IIIA Uterine Corpus Leiomyosarcoma AJCC v8Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT04200443
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Cabozantinib and Nivolumab for Carcinoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT04197310
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 9
- Registration Number
- NCT04173338
- Locations
- 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT04164979
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04151563
- Locations
- 🇷🇴
Local Institution, Timisoara, Romania
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT04149275
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 25
- Registration Number
- NCT04134390
- Locations
- 🇪🇸
Hospital Insular de Gran Canarias, Las Palmas De Gran Canaria, Spain
🇪🇸Hospital Lucus Augusti, Lugo, Spain
🇪🇸Hospital Infanta Sofia, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.